Thran et al. (2017) “mRNA mediates passive vaccination against infectious agents, toxins, and tumors” EMBO Molecular Medicine.
DOI:10.15252/emmm.201707678
Read
about Thran et al. (2017) “mRNA mediates passive vaccination against infectious agents, toxins, and tumors” EMBO Molecular Medicine.
Pardi et al. (2017) “Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge” Nature Communications.
DOI:10.1038/ncomms14630
Read
about Pardi et al. (2017) “Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge” Nature Communications.
Pardi et al. (2017) “Zika virus protection by a single low-dose nucleoside-modified mRNA Vaccination” Nature.
DOI:10.1038/nature21428
Read
about Pardi et al. (2017) “Zika virus protection by a single low-dose nucleoside-modified mRNA Vaccination” Nature.
Pardi et al. (2015) “Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes” Journal of Controlled Release.
DOI:10.1016/j.jconrel.2015.08.007
Read
about Pardi et al. (2015) “Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes” Journal of Controlled Release.
Thess et al. (2015) “Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals” Molecular Therapy.
DOI:10.1038/mt.2015.103
Read
about Thess et al. (2015) “Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals” Molecular Therapy.
Maier et al. (2013) “Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics” Molecular Therapy.
DOI:10.1038/mt.2013.124
Read
about Maier et al. (2013) “Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics” Molecular Therapy.
Mui et al. (2013) “Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles” Molecular Therapy Nucleic Acids.
DOI:10.1038/mtna.2013.66
Read
about Mui et al. (2013) “Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles” Molecular Therapy Nucleic Acids.
Jayaraman et al. (2012) “Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo” Angewandte Chemie.
DOI:10.1002/anie.201203263
Read
about Jayaraman et al. (2012) “Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo” Angewandte Chemie.
Akinc et al. (2010) “Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms” Molecular Therapy.
DOI:10.1038/mt.2010.85
Read
about Akinc et al. (2010) “Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms” Molecular Therapy.
Semple et al. (2010) “Rational design of cationic lipids for siRNA delivery” Nature Biotechnology.
DOI:10.1038/nbt.1602
Read
about Semple et al. (2010) “Rational design of cationic lipids for siRNA delivery” Nature Biotechnology.